

Max Sauter

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9563961/max-sauter-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24 papers	201 citations	8 h-index	13 g-index
29 ext. papers	269 ext. citations	5.4 avg, IF	2.97 L-index

#	Paper	IF	Citations
24	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. <i>Neuro-Oncology</i> , 2022 , 24, i93-i93	1	0
23	Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. <i>Analytical and Bioanalytical Chemistry</i> , 2021 , 413, 5645-5654	4.4	0
22	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1176, 122781	3.2	1
21	Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
20	Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 194, 113728	3.5	1
19	Overcoming the Mucosal Barrier: Tetraether Lipid-Stabilized Liposomal Nanocarriers Decorated with Cell-Penetrating Peptides Enable Oral Delivery of Vancomycin. <i>Advanced Therapeutics</i> , 2021 , 4, 2000247	4.9	3
18	Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , 2020 , 10, 233-239	14	3
17	Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. <i>Journal of Controlled Release</i> , 2020 , 322, 200-208	11.7	16
16	Reporter cell assay-based functional quantification of TNF-Antagonists in serum - a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020 , 596, 113646	3.1	2
15	Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. <i>Analytica Chimica Acta</i> , 2020 , 1114, 42-49	6.6	3
14	Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 186, 113276	3.5	2
13	Development and Validation of an LC-MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. <i>ACS Omega</i> , 2020 , 5, 24329-24339	3.9	2
12	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 2090-2094	3.9	2
11	Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. <i>Bioanalysis</i> , 2019 , 11, 1459-1467	2.1	8
10	Preclinical evaluation of peptide-based radiotracers for integrin $\alpha_5\beta_1$ -positive pancreatic carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019 , 58, 309-318	1.8	3
9	PET/CT Imaging of NSCLC with a $\alpha_5\beta_1$ -Integrin-Targeting Peptide. <i>Molecular Imaging and Biology</i> , 2019 , 21, 973-983	3.8	13
8	An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 174, 633-638	3.5	6

7	An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. <i>Bioanalysis</i> , 2019 , 11, 887-898	2.1	6
6	Comparison of the RGD Motif-Containing Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1679-1685	8.9	26
5	Identification of a Novel ITGBinding Peptide Using Protein Separation and Phage Display. <i>Clinical Cancer Research</i> , 2017 , 23, 4170-4180	12.9	29
4	High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 489-98	8.8	11
3	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. <i>International Journal of Pharmaceutics</i> , 2016 , 512, 87-95	6.5	23
2	Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. <i>Cancer Letters</i> , 2016 , 381, 296-304	9.9	2
1	Radiolabeling strategies for tumor-targeting proteinaceous drugs. <i>Molecules</i> , 2014 , 19, 2135-65	4.8	36